APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis

IntroductionBLyS and APRIL are cytokines from the tumor necrosis factor family which play an important role in systemic lupus erythematosus (SLE). Previous works suggested an association between both molecules and SLE disease activity although their correlation with lupus nephritis is not known. We therefore assessed serum BLyS and APRIL in active lupus nephritis patients.MethodsSerum samples from active lupus nephritis and at 6 months post-treatment were obtained. Serum levels of BLyS and APRIL (n = 47) as well as renal mRNA expression were measured. Serum levels of both molecules and clinical data (n = 27) were available at 6 months follow-up. All biopsy-proven lupus nephritis patients were treated with similar immunosuppressive drugs.ResultsSerum levels of APRIL were associated with proteinuria (Rs = 0.44, P value < 0.01) and degree of histological activity (Rs = 0.34; P value < 0.05) whereas BLyS levels were associated with complement levels (Rs = 0.46; P value < 0.01) and dosage of immunosuppressant. Interestingly, serum APRIL as well as its intrarenal mRNA levels were associated with resistance to treatment. From the receiver operating characteristic (ROC) analysis, high levels (> 4 ng/mL) of serum APRIL predicted treatment failure with a positive predictive value of 93 percent.ConclusionAPRIL could be a potential biomarker for predicting difficult-to-treat cases of lupus nephritis.

[1]  Yoshiya Tanaka.  Anti‐CD20 and other novel biotherapies for systemic lupus erythematosus , 2006 .

[2]  M. Cancro,et al.  The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. , 2009, The Journal of clinical investigation.

[3]  Lee Hebert,et al.  The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Kidney international.

[4]  J. Sánchez-Guerrero,et al.  Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. , 1992, The Journal of rheumatology.

[5]  T. Horiuchi,et al.  Raised serum APRIL levels in patients with systemic lupus erythematosus , 2004, Annals of the rheumatic diseases.

[6]  M. Hegazy,et al.  Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices. , 2010, Clinical immunology.

[7]  M. Madaio,et al.  Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. , 2010, Arthritis and rheumatism.

[8]  T. Fujii,et al.  Expression of BAFF and BAFF‐R in the synovial tissue of patients with rheumatoid arthritis , 2007, Scandinavian journal of rheumatology.

[9]  Don Foster,et al.  TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease , 2000, Nature.

[10]  S. Dillon,et al.  An APRIL to remember: novel TNF ligands as therapeutic targets , 2006, Nature Reviews Drug Discovery.

[11]  J. Q. Rosso,et al.  B Cell-Targeted Therapies for Systemic Lupus Erythematosus: An Update on Clinical Trial Data , 2011 .

[12]  D. Hilbert,et al.  B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels , 2005, Arthritis research & therapy.

[13]  M. Petri,et al.  Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. , 2008, Arthritis and rheumatism.

[14]  B. Diamond,et al.  Similarities and differences between selective and nonselective BAFF blockade in murine SLE. , 2006, The Journal of clinical investigation.

[15]  R. Bram,et al.  BLyS and APRIL in rheumatoid arthritis. , 2005, The Journal of clinical investigation.

[16]  M. Suthanthiran,et al.  Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. , 2001, The New England journal of medicine.

[17]  J. Tschopp,et al.  Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. , 2002, The Journal of clinical investigation.

[18]  Amy S Orr,et al.  BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. , 1999, Science.

[19]  C. Berek,et al.  Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[20]  D. Isenberg,et al.  The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. , 2011, Rheumatology.

[21]  D. Boumpas,et al.  Outcome criteria for lupus nephritis trials: A critical overview , 1998, Lupus.

[22]  Kelly M Ennis,et al.  Belimumab: A BLyS-Specific Inhibitor for Systemic Lupus Erythematosus , 2010, The Annals of pharmacotherapy.

[23]  J. Hillert,et al.  Increased levels of APRIL (A Proliferation-Inducing Ligand) mRNA in multiple sclerosis , 2005, Journal of Neuroimmunology.

[24]  G. Ferraccioli,et al.  B cell depletion may lead to normalization of anti-platelet,anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus , 2004, Thrombosis and Haemostasis.

[25]  Ashutosh Kumar Singh,et al.  The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. , 2006, Arthritis and rheumatism.

[26]  D. Lacey,et al.  Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Hilbert,et al.  The discovery and development of belimumab: the anti-BLyS–lupus connection , 2012, Nature Biotechnology.

[28]  C. Cohen,et al.  Intrarenal production of B-cell survival factors in human lupus nephritis , 2011, Modern Pathology.

[29]  J. Tschopp,et al.  Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations , 1999, The Journal of experimental medicine.

[30]  M. Petri,et al.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[31]  C. Gordon,et al.  Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. , 2010, Arthritis and rheumatism.

[32]  K. Eriksson,et al.  Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms , 2008, Arthritis research & therapy.

[33]  A. Rajeswaran,et al.  Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial , 2012, Arthritis Research & Therapy.

[34]  M. Hahne,et al.  Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus , 2008, Annals of the rheumatic diseases.

[35]  L R Muenz,et al.  Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. , 1984, Kidney international.

[36]  V. Sharma,et al.  Messenger RNA for FOXP3 in the urine of renal-allograft recipients. , 2005, The New England journal of medicine.

[37]  B. Nardelli,et al.  DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL , 2002, Nature Immunology.

[38]  J. Browning.  B cells move to centre stage: novel opportunities for autoimmune disease treatment , 2006, Nature Reviews Drug Discovery.

[39]  V. Roschke,et al.  B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. , 2003, Arthritis and rheumatism.

[40]  I. Sanz,et al.  B cells as therapeutic targets in SLE , 2010, Nature Reviews Rheumatology.

[41]  I. Sanz,et al.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. , 2004, Arthritis and rheumatism.